Codex Capital Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Codex Capital Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34M	Sell	3,000 -4,320	-59%	-$2.01M	0.52%	28
2025 Q4	$3.32M	Buy	7,320 +70	+1%	+$30.2K	1.21%	22
2025 Q3	$2.84M	Sell	7,250 -4,500	-38%	-$1.88M	1.07%	24
2025 Q2	$5.23M	Hold	11,750	–	–	2.09%	18
2025 Q1	$5.7M	Hold	11,750	–	–	2.68%	17
2024 Q4	$4.73M	Hold	11,750	–	–	2.09%	21
2024 Q3	$5.46M	Hold	11,750	–	–	2.42%	16
2024 Q2	$5.51M	Buy	+11,750	New	+$5.1M	2.52%	17

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Codex Capital Asset Management's VRTX Position: Q1 2026 in Review

Codex Capital Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 59% in Q1 2026, selling an estimated $2.01M and leaving 3,000 shares worth $1.34M. The position accounts for 0.52% of the portfolio, ranked #28.

Codex Capital Asset Management first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $5.7M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Codex Capital Asset Management held 3,000 shares of Vertex Pharmaceuticals worth $1.34M as of Q1 2026.
Codex Capital Asset Management sold 4,320 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.01M.
Vertex Pharmaceuticals made up 0.52% of Codex Capital Asset Management's portfolio in Q1 2026, its #28 holding.
Codex Capital Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Codex Capital Asset Management's Vertex Pharmaceuticals position peaked at $5.7M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Codex Capital Asset Management's 13F filing for Q1 2026, filed 16 Apr 2026.